Imago BioSciences, Inc.
CIK 0001623715Emerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2021
Revenue
—
Net Income
$-42.31M
Total Assets
$224.79M
Equity
$214.69M
Shares Out
33.82M
Op. Cash Flow
$-39.76M
Business
Imago BioSciences, Inc. is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|
| Research and development | 32 | 15 | |
| General and administrative | 10 | 3 | |
| Total operating expenses | 43 | 18 | |
| Loss from operations | −43 | −18 | |
| Interest income | 314,000 | 48,000 | |
| Change in fair value of convertible preferred stock tranche liability | — | 214,000 | |
| Other expense, net | −99,000 | −20,000 | |
| Total other income, net | 215,000 | 242,000 | |
| Loss before income tax expense | −42 | −18 | |
| Income tax expense | −2,000 | −3,000 | |
| Net loss | −42 | −18 | |
| Net loss per share, basic and diluted | −2.7 | −17.49 | |
| Weighted-average shares used in computing net loss per share, basic and diluted | 16 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 11 | 19 | — | |
| Short-term investments | 206 | 57 | — | |
| Prepaid expenses and other current assets | 4 | 1 | — | |
| Total current assets | 221 | 78 | — | |
| Property and equipment, net | 2,000 | 8,000 | — | |
| Long-term investments | — | 20 | — | |
| Other long-term assets | 3 | 1 | — | |
| Total assets | 225 | 99 | — | |
| Accounts payable | 3 | 1 | — | |
| Accrued and other current liabilities | 7 | 4 | — | |
| Total current liabilities | 10 | 5 | — | |
| Commitments and contingencies (Note 6) | — | — | — | |
| Convertible preferred stock, $0.0001 par value; 0 and 180,059,639 shares authorized, as of December 31, 2021 and 2020, respectively; 0 and 21,435,632 issued and outstanding as of December 31, 2021 and 2020, respectively; aggregate liquidation preference of $0 as of December 31, 2021 | 0 | 163 | — | |
| Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of December 31, 2021 and 2020, respectively; 0 issued and outstanding as of December 31, 2021 and 2020, respectively | 0 | 0 | — | |
| Common stock, $0.0001 par value; 300,000,000 and 228,300,000 shares authorized as of December 31, 2021 and 2020, respectively; 33,531,743 and 1,030,023 shares issued and outstanding as of December 31, 2021 and 2020, respectively | 3,000 | 0 | — | |
| Additional paid-in capital | 327 | 2 | — | |
| Accumulated other comprehensive income (loss) | −43,000 | −3,000 | — | |
| Accumulated deficit | −113 | −70 | — | |
| Total stockholders' equity (deficit) | 215 | −69 | −51 | |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | 225 | 99 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|
| Net loss | −42 | −18 | |
| Amortization of premium and discounts on available-for-sale investments | 109,000 | 6,000 | |
| Depreciation and amortization | 6,000 | 1,000 | |
| Stock-based compensation | 2 | 426,000 | |
| Prepaid expenses and other current assets | −3 | −393,000 | |
| Other long-term assets | −2 | −1 | |
| Accounts payable | 2 | 8,000 | |
| Accrued expenses and other current liabilities | 3 | 2 | |
| Net cash used in operating activities | −40 | −17 | |
| Purchases of property and equipment | — | −9,000 | |
| Purchases of available-for-sale investments | −208 | −81 | |
| Proceeds from maturities of available-for-sale investments | 79 | 7 | |
| Net cash used in investing activities | −129 | −74 | |
| Payments of offering costs related to initial public offering | −3 | — | |
| Proceeds from exercise of stock options | 506,000 | 29,000 | |
| Net cash provided by financing activities | 161 | 106 | |
| Net (decrease) increase in cash and cash equivalents | −8 | 14 | |
| Cash paid for taxes | 74,000 | 14,000 | |
| Settlement of Convertible preferred stock liability in connection with the issuance of Series B convertible preferred stock | — | 2 | |
| Conversion of convertible preferred stock to common stock upon initial public offering | 163 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro